Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease
about
New combinations in the treatment of COPD: rationale for aclidinium-formoterolFormoterol therapy for chronic obstructive pulmonary disease: a review of the literature.Combined budesonide/formoterol turbuhaler treatment of asthma.Enantio-separation of drugs with multiple chiral centers by chromatography and capillary electrophoresis.Formoterol: a review of its use in chronic obstructive pulmonary disease.Stereoselective urinary excretion of formoterol and its glucuronide conjugate in humanLong-acting beta 2-agonists. Role in primary care asthma treatment.Budesonide-formoterol (inhalation powder) in the treatment of COPD.Formoterol in the management of chronic obstructive pulmonary disease.Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma.Evaluation of combination long-acting beta-2 agonists and inhaled glucocorticosteroids for treatment of asthma.Budesonide/formoterol dry powder in asthma: an option for control as maintenance and reliever therapy.Budesonide/formoterol Turbuhaler®: a review of its use in chronic obstructive pulmonary disease.Mometasone/formoterol inhalation aerosol: in asthma uncontrolled on medium- or high-dose inhaled corticosteroids.Beta-Adrenergic AgonistsModulite technology in the development of formoterol HFA pMDI: clinical evidence and future opportunities.Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung.Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial.Quantitative detection of inhaled formoterol in human urine and relevance to doping control analysis.Inhaled beclometasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: evidence and future perspectives
P2860
Q26765303-DE3F406F-CF10-4524-9EE2-44E58536A79AQ34834664-088FDBF2-2FE2-4292-90B8-8DB1F274E4BAQ35009462-07EECCC1-AA79-44AF-802B-4E54DB2D7894Q35213968-B79FAD6C-A9D1-4BBF-AB58-FE3F2960BCDFQ35627824-CF3B24D3-A7E2-43EF-BC1E-C4CA764E74D2Q35804014-1E4F7E55-3699-4FBB-8832-BCBD8831485CQ36479702-FB21A2C1-B546-44E2-AE35-DF40C2330E42Q37018887-EBE30C38-879E-40CF-BA76-62D1E455064EQ37070307-3F72D70B-0A91-4495-B5F2-E37B512029F4Q37362634-AAEE28F7-0471-45DD-A750-79F19C870881Q37556546-CB1ABB7D-B757-4065-AEF3-441DB3FFE7C8Q37678433-D7B85BD1-B053-4494-8479-51C35FAD378AQ37982436-23A1F1D3-9A10-43E2-ABE7-63816A483B3CQ38008474-3DDCBE2F-C3F9-4655-A08E-72C240CE8957Q38974241-3AFF8728-3C5C-4082-ACA5-5ECCD4E9B0BFQ40129417-E1D8EF27-8053-4D7E-8C8B-9EAA7ED68474Q41846220-2A80A65E-8C14-4AD6-88A6-2C7D4A380F27Q43912252-574D2418-CCA0-4171-A157-873100D82696Q47983804-B61C1586-9FC9-46F2-95DE-AA8523671409Q58877120-539D25DF-032F-4FB3-AC57-4D07B25A08B5
P2860
Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease
description
1991 nî lūn-bûn
@nan
1991 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Formoterol. A review of its ph ...... le obstructive airways disease
@ast
Formoterol. A review of its ph ...... le obstructive airways disease
@en
Formoterol. A review of its ph ...... le obstructive airways disease
@nl
type
label
Formoterol. A review of its ph ...... le obstructive airways disease
@ast
Formoterol. A review of its ph ...... le obstructive airways disease
@en
Formoterol. A review of its ph ...... le obstructive airways disease
@nl
prefLabel
Formoterol. A review of its ph ...... le obstructive airways disease
@ast
Formoterol. A review of its ph ...... le obstructive airways disease
@en
Formoterol. A review of its ph ...... le obstructive airways disease
@nl
P2093
P1433
P1476
Formoterol. A review of its ph ...... le obstructive airways disease
@en
P2093
L M Hollingshead
P304
P356
10.2165/00003495-199142010-00007
P407
P577
1991-07-01T00:00:00Z
P6179
1024242907